Cynata Therapeutics Ltd

Mesenchymal stromal cells (MSCs) have long been regarded as one of nature’s most powerful repair systems—cells with the ability to reduce inflammation, regulate immune responses and stimulate tissue healing. For decades, they have been seen as a potential foundation for an entirely new class of medicine. Cynata Therapeutics (ASX: CYP) is a Melbourne-based biotech advancing […]

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]

Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cells (MSCs) products and research. In a statement to the market, Cynata said it had received ethics committee approval to commence a clinical trial in Australia to investigate early efficacy of Cymerus MSCs in adults admitted […]

Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding using its Cymerus mesenchymal stem cell (MSC) platform to treat COVID-19 patients that develop severe symptoms. According to Cynata, COVID-19 has caused serious ongoing issues including acute respiratory distress syndrome, sepsis and cytokine release syndrome. The company […]